University Hospital Düsseldorf / CIO Düsseldorf
Düsseldorf's university hospital, a partner in the CIO cancer centre alliance and a leading site for FAPI and PSMA imaging under Frederik Giesel.
University Hospital Düsseldorf forms, with Aachen, Bonn and Cologne, the Centrum für Integrierte Onkologie (CIO ABCD), a German Cancer Aid Oncology Center of Excellence. Its nuclear medicine department is directed by Frederik Giesel, co-inventor of FAPI PET tracers at Heidelberg, and runs theranostic programmes in prostate and neuroendocrine cancers. The hospital has a large paediatric oncology and haematology department, hepatology and liver cancer programmes, and neurosurgical oncology. Trials from the CIO network give patients access to early-phase immunotherapy and cell therapy studies.
- FAPI and PSMA PET
- Theranostics
- Paediatric oncology
- CIO ABCD
Pages like this
not linked directly; found by shared links- PersonUwe Haberkorn
Shares FAP-2286 (177Lu / 68Ga), Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
- InstitutionPostgraduate Institute of Medical Education and Research, Chandigarh
Shares FAPI PET, Lutetium-177 vipivotide tetraxetan, PSMA PET, Neuroendocrine tumours.
- PersonRahul Aggarwal
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionEuropean Association of Nuclear Medicine
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, FAPI PET, Lutetium-177 vipivotide tetraxetan.
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares FAPI PET, Lutetium-177 vipivotide tetraxetan, PSMA PET, Neuroendocrine tumours.
- PersonMichael J. Morris
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).